Qiagen (NYSE:QGEN) Updates Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.620- for the period, compared to the consensus estimate of 0.630. The company issued revenue guidance of $538.3 million-$543.7 million, compared to the consensus revenue estimate of $552.7 million.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $43.00 target price on shares of Qiagen in a research note on Thursday, April 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Qiagen in a research note on Thursday. TD Cowen reiterated a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Weiss Ratings lowered shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 29th. Finally, Stifel Nicolaus set a $36.00 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $42.43.

Qiagen Trading Down 0.6%

Shares of NYSE QGEN traded down $0.24 during trading hours on Thursday, reaching $41.71. The stock had a trading volume of 4,028,165 shares, compared to its average volume of 2,871,472. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The firm has a market cap of $8.59 billion, a price-to-earnings ratio of 21.37, a P/E/G ratio of 4.19 and a beta of 0.63. The business’s fifty day moving average price is $39.32 and its two-hundred day moving average price is $41.69. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.00 million for the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts expect that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The business also recently announced an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were paid a $0.35 dividend. This represents a yield of 90.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date was Tuesday, July 7th. Qiagen’s payout ratio is presently 18.32%.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen reported second-quarter adjusted EPS of $0.62, above the $0.60 consensus estimate, while revenue of $535 million exceeded expectations of $527.5 million. Revenue was broadly unchanged year over year, but the company said its growth pillars delivered 5% growth at constant exchange rates and that sales exceeded its prior outlook for a decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 EPS outlook of approximately $2.43, in line with analyst expectations, while maintaining high profitability. Qiagen Earnings Conference Call
• Neutral Sentiment: Management’s second-quarter earnings call and presentation provided additional detail on the performance of Qiagen’s growth pillars and the company’s outlook, but did not materially change the full-year EPS forecast. Qiagen N.V. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter guidance was below consensus: EPS of $0.62 versus $0.63 expected and revenue of $538.3 million to $543.7 million versus $552.7 million expected. The revenue shortfall indicates analysts may need to reduce near-term estimates.
• Negative Sentiment: Although full-year EPS guidance matched consensus, full-year revenue guidance of roughly $2.1 billion was below the approximately $2.2 billion analyst estimate, tempering the impact of the quarterly beat.

Institutional Trading of Qiagen

Institutional investors have recently modified their holdings of the company. Danske Bank A S purchased a new stake in Qiagen during the third quarter valued at approximately $36,000. Global Retirement Partners LLC boosted its holdings in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after acquiring an additional 851 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Qiagen during the third quarter worth about $64,000. Kestra Advisory Services LLC purchased a new stake in shares of Qiagen during the fourth quarter worth about $70,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Qiagen during the fourth quarter valued at about $73,000. 70.00% of the stock is currently owned by institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.